Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Aravive, Inc. (ARAV)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
3.3900-0.1100 (-3.14%)
At close: 1:00PM EST
Advertisement
Sign in to post a message.
  • s
    scott
    someone wants this stock
  • Y
    Yassen
    Anyone still in :).
  • K
    Kevin
    Well, that didn't last long. Can we just get at least a day with a healthy gain on good news?! Similar thing happened in June when it ran up 30% pre-market only to retreat back quickly after the opening bell.
  • Y
    Yahoo Finance Insights
    Aravive reached a 52 Week low at 3.35
  • Y
    Yahoo Finance Insights
    Aravive is up 5.57% to 4.17
  • Y
    Yahoo Finance Insights
    Aravive is up 5.79% to 4.02
  • Y
    Yahoo Finance Insights
    Aravive is up 8.17% to 3.84
  • Y
    Yahoo Finance Insights
    Aravive is down 8.74% to 3.55
  • V
    VenkatS
    Accumulation has to happen this week as the Q closes! Mutual funds and institutions should be buying.

    I am expecting them to release new updates before Sept 30 (before the Fireside chat! )
    Bullish
  • s
    scott
    A good day, news soon?
  • s
    scott
    I will buy more under 4.
  • C
    Chari
    Lets keep the news flowing..

    Aravive and 3D Medicines Announce Strategic Collaboration to Develop and Commercialize AVB-500 in Greater China
    31 minutes ago
    GlobeNewswire
    Related Investments: Aravive Inc
    --Aravive, Inc., a clinical-stage oncology company developing transformative therapeutics, and 3 D Medicines Inc., a China- based biopharmaceutical company developing next-generation immuno-oncology drugs, today announced a collaboration and exclusive license agreement for the development and commercialization of AVB-500 across all oncology...
  • J
    Julian
    “We are enthusiastic about the clinical data with AVB-500 in combination with anticancer therapies that continue to show consistent PK/PD data and a favorable safety profile. These combinations may have the potential to be used in a range of different cancers.”

    It’s important that at any stage a drug can fail, but “consistent PK/PD” is one of the fastest and difficult to predict ways. I think this will creep up like all biotech as the probability of getting to the market vets higher and higher
  • T
    Trevor
    Just remember, a board member purchased 2.875 million shares of common stock at $7.29 pps. Anything under that price is a great entry point IMO. I’m holding about 6,000 shares around current price since last year. Could have sold in March and netted over $24k but this baby is going to get a lot closer to the current price target of $26.
  • T
    Tom
    Finally, some sort of move.
  • D
    DoyourownDD
    Arav currently approx.. $98 Mill Market Cap and $28 Mill Enterprise Value AND lead drug advancing to phase 3 with “Aravive’s collaboration and license agreement with 3D Medicines Inc. is for the development and commercialization of AVB-500 in oncology indications in Greater China. Under the terms of the agreement, Aravive is eligible to receive up to an aggregate of $207 million in development and commercial milestone payments and royalties.”
    wow appears SP may be way undervalued if approved? 207/28=7.25 x 4.5(current stock price)=$32.62/SP based on enterprise value and just greater china potential revenue on lead drug candidate potential??? do your own due diligence. NOT financial advice.
    Bullish
  • d
    dakdan
    yes it does have potential but remember this is only a phase 1 Study still years out before FDA approval
  • s
    scott
    last chance under 5.
  • B
    Bobbafet
    50%? Try 300%... check out their investor presentation cancer is growing at an enormous rate. They have a product that has multiple revenue streams. Even a 500 million market cap in my opinion is low compared to what they have to offer. Their partner with 3D will bring in up to 200 million with royalties just in China. Wait till they expand their product. $$$
    Bullish
  • K
    K
    Holding the bag that keeps bottom hole getting bigger by the day.
Advertisement
Advertisement